Grail (NASDAQ:GRAL – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55, Zacks reports.
Grail Stock Down 9.2 %
Shares of GRAL traded down $4.84 during trading hours on Thursday, reaching $47.76. 1,560,490 shares of the company traded hands, compared to its average volume of 1,459,752. The stock has a fifty day simple moving average of $25.78 and a 200 day simple moving average of $18.86. Grail has a fifty-two week low of $12.33 and a fifty-two week high of $63.99.
Analyst Ratings Changes
Several equities analysts recently weighed in on GRAL shares. Morgan Stanley assumed coverage on Grail in a research note on Wednesday, November 27th. They issued an “equal weight” rating and a $16.00 price objective for the company. Wolfe Research assumed coverage on shares of Grail in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock.
Grail Company Profile
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
- Five stocks we like better than Grail
- What is a Secondary Public Offering? What Investors Need to Know
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Short Selling – The Pros and Cons
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
